Pinealon
Tripeptide (Glu-Asp-Arg) from pineal gland. Russian research program studied it for neuroprotective and longevity properties.
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed as part of the Russian bioregulator peptide research program, primarily through the work of Vladimir Khavinson's group. It was designed based on peptides extracted from the pineal gland and has been studied for neuroprotective effects, cognitive support in aging, and regulation of the circadian system including melatonin.
- Neuroprotective effects in animal models of oxidative stress and hypoxia.
- Russian clinical studies report cognitive improvements in elderly patients.
- Proposed influence on melatonin production and circadian regulation.
- Research base is predominantly from a single Russian research group and has not been independently replicated.
The research on Pinealon shares the general limitations of the Russian bioregulator program — studies are mostly from a single institution, have not been replicated in large independent trials, and have not received regulatory review outside of Russia. It is not FDA-approved. Claims about its cognitive and circadian effects in healthy individuals are not supported by independent clinical trial evidence.
The pineal gland, located deep in the brain, produces melatonin and plays a central role in regulating sleep-wake cycles and circadian rhythm. Pinealon is composed of three amino acids derived from pineal gland proteins. Researchers propose that these short peptides act as regulatory signals that can enter neurons and interact with DNA-binding processes, potentially upregulating genes involved in antioxidant defense and melatonin synthesis. The mechanism is described as epigenetic regulation — influencing which genes are expressed rather than changing the genes themselves. This is a proposed mechanism based on preclinical work; the specific molecular interactions have not been fully characterized in human studies.
Pinealon has been reported as well-tolerated in published Russian studies, with no significant adverse effects described. The independent safety evidence base is limited. It is not FDA-approved. As with other research peptides, purity and sterility of research-grade material are important practical considerations.
Most evidence comes from preclinical studies and case reports. Human data is limited and more research is needed.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
39 sources · Platform research library · Not generated by AI
Combination use is not endorsed - provided for research context only.
Want More Detailed Research?
Ask the AI anything about Pinealon - mechanisms, trial summaries, pharmacokinetics, and comparisons.
Ask AI About Pinealon